# ANOS1 Facilitated Tumorigenesis in Gastric Cancer through the Regulation of Oxidative Phosphorylation Pathway

**Authors:** Liping Tao, Wen Ming, Xianfei Wang

PMC · DOI: 10.4014/jmb.2511.11048 · 2026-02-26

## TL;DR

This study finds that ANOS1 promotes gastric cancer by altering tumor cell metabolism and influencing the immune environment.

## Contribution

The novel contribution is identifying ANOS1 as a key regulator of gastric cancer through oxidative phosphorylation and its impact on immune infiltration.

## Key findings

- ANOS1 is highly expressed in gastric cancer and promotes tumor cell migration, invasion, and proliferation.
- ANOS1 knockdown increases oxidative phosphorylation and reduces glycolysis in tumor cells.
- ANOS1 expression correlates with M2-type macrophage abundance in the tumor microenvironment.

## Abstract

Gastric cancer (GC) is the fifth leading cause of cancer-related deaths, with poor early detection and prognosis. Biomarkers related to its development are desperately needed. This study explores ANOS1 expression in GC and its mechanism in tumor metabolic reprogramming. Core molecules were identified via co-expression analysis of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) data. RT-PCR and Western blot were used to confirm the levels of ANOS1 in GC and normal tissues. Assays conducted both in vitro and in vivo verified that ANOS1 accelerates the development of GC. Seahorse XF was used to quantify oxygen consumption rate and extracellular acidification rate as well as glucose absorption, lactate generation, and mtROS levels. Finally, the correlation between the ANOS1 and immune infiltration in gastric cancer was analyzed. Weighted Gene Co-expression Network Analysis of TCGA and GEO datasets identified 44 candidates, from which six prognostic genes were further pinpointed using univariate Cox and least absolute shrinkage and selection operator regression analyses. Gene Set Enrichment Analysis revealed ANOS1 as a potential core regulator. ANOS1 was highly expressed in GC and promoted migration, invasion, and proliferation. Mechanistically, knockdown of ANOS1 promotes oxidative phosphorylation via the receptor tyrosine kinase pathway, suppresses glycolysis, and inhibits the proliferative, migratory, and invasive capacities of tumor cells. The results of immune infiltration analysis revealed that ANOS1 expression was exhibited a positive correlation with the abundance of M2-type macrophages. ANOS1 is up-regulated in GC. As a key regulatory factor of gastric cancer, ANOS1 is involved in the metabolic regulation of tumor cells and may have an impact on prognosis and the immune microenvironment.

## Linked entities

- **Genes:** ANOS1 (anosmin 1) [NCBI Gene 3730]
- **Diseases:** gastric cancer (MONDO:0001056)

## Full-text entities

- **Genes:** SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714] {aka ASV, SRC1, THC6, c-SRC, p60-Src}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, COL5A2 (collagen type V alpha 2 chain) [NCBI Gene 1290] {aka EDSC, EDSCL2}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, FEN1 (flap structure-specific endonuclease 1) [NCBI Gene 2237] {aka FEN-1, MF1, RAD2}, RNASE1 (ribonuclease A family member 1, pancreatic) [NCBI Gene 6035] {aka RAC1, RIB1, RNS1}, HK1 (hexokinase 1) [NCBI Gene 3098] {aka CNSHA5, HK, HK1-ta, HK1-tb, HK1-tc, HKD}, LAMC2 (laminin subunit gamma 2) [NCBI Gene 3918] {aka B2T, BM600, CSF, EBR2, EBR2A, JEB3A}, PSG2 (pregnancy specific beta-1-glycoprotein 2) [NCBI Gene 5670] {aka CEA, PSBG2, PSG1}, NID2 (nidogen 2) [NCBI Gene 22795] {aka NID-2}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, ARG1 (arginase 1) [NCBI Gene 383], BLNK (B cell linker) [NCBI Gene 29760] {aka AGM4, BASH, BLNK-S, LY57, SLP-65, SLP65}, TFB1M (transcription factor B1, mitochondrial) [NCBI Gene 51106] {aka CGI-75, CGI75, mtTFB, mtTFB1}, PLAU (plasminogen activator, urokinase) [NCBI Gene 5328] {aka ATF, BDPLT5, QPD, UPA, URK, u-PA}, NDUFA13 (NADH:ubiquinone oxidoreductase subunit A13) [NCBI Gene 51079] {aka B16.6, CDA016, CGI-39, GRIM-19, GRIM19, MC1DN28}, CTHRC1 (collagen triple helix repeat containing 1) [NCBI Gene 115908], PPT1 (palmitoyl-protein thioesterase 1) [NCBI Gene 5538] {aka CLN1, INCL, PPT}, RET (ret proto-oncogene) [NCBI Gene 5979] {aka CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, MRPS7 (mitochondrial ribosomal protein S7) [NCBI Gene 51081] {aka COXPD34, MRP-S, MRP-S7, RP-S7, RPMS7, S7mt}, FGFR1 (fibroblast growth factor receptor 1) [NCBI Gene 2260] {aka BFGFR, CD331, CEK, ECCL, FGFBR, FGFR-1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, GPX3 (glutathione peroxidase 3) [NCBI Gene 2878] {aka GPx-P, GSHPx-3, GSHPx-P}, GNRH1 (gonadotropin releasing hormone 1) [NCBI Gene 2796] {aka GNRH, GRH, LHRH, LNRH}, BGN (biglycan) [NCBI Gene 633] {aka DSPG1, MRLS, PG-S1, PGI, SEMDX, SLRR1A}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, NDUFS3 (NADH:ubiquinone oxidoreductase core subunit S3) [NCBI Gene 4722] {aka CI-30, MC1DN8}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, ANOS1 (anosmin 1) [NCBI Gene 3730] {aka ADMLX, HH1, HHA, KAL, KAL1, KALIG-1}
- **Diseases:** OXPHOS deficiencies (MESH:D028361), lung cancer (MESH:D008175), Tumor (MESH:D009369), metastatic (MESH:D000092182), GC (MESH:D013274), oncogenic (MESH:D000074723), tumorigenesis (MESH:D063646), reproductive abnormalities (MESH:D060737), KS (MESH:D017436), Lung Metastasis (MESH:D009362), tumorigenic (MESH:D002471), colorectal cancer (MESH:D015179), breast cancer (MESH:D001943), ovarian cancer (MESH:D010051)
- **Chemicals:** methanol (MESH:D000432), PS (MESH:D010758), oxygen (MESH:D010100), L-Lactate (MESH:D019344), Cardamonin (MESH:C436747), 2-DG (MESH:D003847), streptomycin (MESH:D013307), CCK-8 (MESH:D012844), MitoSOX Red (MESH:C000597839), Trizol (MESH:C411644), SDS (MESH:D012967), SUN11602 (MESH:C584014), FCCP (MESH:D002259), MitoTracker (-), HS (MESH:D006497), 2-NBDG (MESH:C098340), crystal violet (MESH:D005840), phenol red (MESH:D010637), H&amp;E (MESH:D006371), penicillin (MESH:D010406), Puromycin (MESH:D011691), HEPES (MESH:D006531), ATP (MESH:D000255), Rotenone (MESH:D012402), CO2 (MESH:D002245), glutamine (MESH:D005973), SYBR Green (MESH:C098022), polybrene (MESH:D006583), antimycin A (MESH:D000968), paraformaldehyde (MESH:C003043), CMXRos (MESH:C107472), PVDF (MESH:C024865), Glucose (MESH:D005947), Oligomycin (MESH:D009840)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Mycoplasma (genus) [taxon 2093], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** S0061S, C with 100
- **Cell lines:** shANOS1 — Mus musculus (Mouse), Hybridoma (CVCL_C7RB), HEK293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), MKN45 — Homo sapiens (Human), Gastric adenocarcinoma, Cancer cell line (CVCL_0434), GES-1 — Homo sapiens (Human), Transformed cell line (CVCL_EQ22), AGS — Homo sapiens (Human), Gastric adenocarcinoma, Cancer cell line (CVCL_0139), HGC27 — Homo sapiens (Human), Gastric carcinoma, Cancer cell line (CVCL_1279)

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12975496/full.md

---
Source: https://tomesphere.com/paper/PMC12975496